Propanc Biopharma, Inc. (PPCB)
NASDAQ: PPCB · Real-Time Price · USD
1.080
-0.020 (-1.82%)
At close: Aug 21, 2026, 4:00 PM EDT
1.050
-0.030 (-2.78%)
After-hours: Aug 21, 2026, 7:59 PM EDT
Propanc Biopharma Employees
As of June 30, 2025, Propanc Biopharma had 2 total employees, including 1 full-time and 1 part-time employees. The number of employees did not change compared to the previous year.
Employees
2
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$9,646,588
Market Cap
2.46M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Jun 30, 2025 | 2 | 0 | - | 1 | 1 |
| Jun 30, 2024 | 2 | 0 | - | 1 | 1 |
| Jun 30, 2023 | 2 | -1 | -33.33% | 1 | 1 |
| Jun 30, 2022 | 3 | 1 | 50.00% | 1 | 2 |
| Jun 30, 2021 | 2 | -1 | -33.33% | 1 | 1 |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Valion Bio | 52 |
| Virax Biolabs Group | 26 |
| Curis | 24 |
| Silexion Therapeutics | 14 |
| Decoy Therapeutics | 11 |
| CDT Equity | 4 |
| Oragenics | 3 |
| 60 Degrees Pharmaceuticals | 3 |
PPCB News
- 5 days ago - Propanc Biopharma starts finalization of clinical trial protocol for PRP study - TheFly
- 5 days ago - Propanc Biopharma Clears Path for World-First Phase 1b Clinical Study of Breakthrough Cancer Therapy PRP - GlobeNewsWire
- 6 days ago - Propanc highlights PRP as potential therapy against RAS-driven cancers - TheFly
- 11 days ago - Propanc Biopharma Highlights Differentiated Proenzyme Therapy PRP as a Potential Therapy of Choice Against RAS-Driven Cancers - GlobeNewsWire
- 17 days ago - Propanc reports new preclinical data for PRP in pancreatic ductal adenocarcinoma - TheFly
- 17 days ago - Propanc Biopharma Announces Positive Preclinical and Early Translational Data for PRP Showing >90% Tumor Growth Inhibition and Significant Survival Benefit in Pancreatic Ductal Adenocarcinoma Models - GlobeNewsWire
- 18 days ago - Propanc Biopharma Completes First Tranche of $5.0 Million Share Repurchase Program - GlobeNewsWire
- 4 weeks ago - Propanc Biopharma Publishes Evaluation of Recombinant Trypsinogen & Chymotrypsinogen in Peer Reviewed Journal - GlobeNewsWire